Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Nuclear Medicine Communications|March 29, 2019
Can 18F-FDG PET/CT diagnose malignant change in benign chondroid tumors?Nilendu C Purandare, Ameya Puranik, Sneha Shah, et al.
World Journal of Nuclear Medicine|October 1, 2015
Designing of High-Volume PET/CT Facility with Optimal Reduction of Radiation Exposure to the Staff: Implementation and Optimization in a Tertiary Health Care Facility in IndiaAshish Kumar Jha, Abhijith Mohan Singh, Sneha Mithun, et al.
Indian Journal of Nuclear Medicine : IJNM : the Official Journal of the Society of Nuclear Medicine, India|February 13, 2018
Reduction of Radiation Exposure to Patients and Professionals by Reducing the Administered Activity of 18F-Fluorodeoxyglucose in a Positron-emission Tomography/Computed Tomography StudySneha Mithun, Ashish Kumar Jha, Ameya D Puranik, et al.
Nuclear Medicine Communications|August 15, 2013
90Y microsphere therapy: does 90Y PET/CT imaging obviate the need for 90Y Bremsstrahlung SPECT/CT imaging?Anand A Zade, Venkatesh Rangarajan, Nilendu C Purandare, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|January 25, 2011
Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findingsNilendu C Purandare, Venkatesh Rangarajan, Sneha A Shah, et al.
Nuclear Medicine Communications|August 1, 2020
Does 68Ga-DOTA-NOC-PET/CT impact staging and therapeutic decision making in pulmonary carcinoid tumors?Nilendu C Purandare, Ameya Puranik, Archi Agrawal, et al.
World Journal of Nuclear Medicine|March 20, 2020
Prognostic value of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography-computed tomography in surgically resected non-small cell lung cancer patientsBoon Mathew, Nilendu C Purandare, Ameya Puranik, et al.
Nuclear Medicine Communications|May 17, 2016
Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapyAshish K Jha, Sneha Mithun, Nilendu C Purandare, et al.
Nuclear Medicine Communications|April 23, 2014
Incremental value of 18F-FDG PET/CT in therapeutic decision-making of potentially curable esophageal adenocarcinomaNilendu C Purandare, C S Pramesh, George Karimundackal, et al.
Nuclear Medicine Communications|September 19, 2017
Common malignant brain tumors: can 18F-FDG PET/CT aid in differentiation?Nilendu C Purandare, Ameya Puranik, Sneha Shah, et al.
Pageof 9